{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:48:50Z","timestamp":1791787730312,"version":"4.3.4"},"reference-count":63,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"DOI":"10.1080\/10428194.2026.2743355","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:37:38Z","timestamp":1791787058000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Emerging drug profile: bexobrutideg"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4021-3433","authenticated-orcid":false,"given":"Tiana","family":"Huynh","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5474-8598","authenticated-orcid":false,"given":"Sonia","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,11]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02027"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0520"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148457"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026672"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3837426\/v1"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12974"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13427"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008447"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02380"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00166"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147516"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2020.00009"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00551-9"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196515"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00216"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0055-1"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2017.10.005"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.8b01094"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-86"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7003"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204184"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Linton KF Francesco Lewis D Riches J et\u00a0al. Robust Bruton\u2019s tyrosine kinase (BTK) degradation with NX-5948 an oral BTK degrader in a first-in-human phase 1a trial in patients with relapsed\/refractory B cell malignancies. International Conference on Machine Learning; Lugano Switzerland 2023.","DOI":"10.1097\/01.HS9.0000975912.59317.8d"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2850"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.64898\/2026.08.01.740538"},{"key":"e_1_3_2_37_1","volume-title":"TPD & Induced Proximity Summit","author":"O\u2019Connor P","year":"2024","unstructured":"O\u2019Connor P, editor Clinical activity of NX-5948: a first-in-class BTK degrader. In TPD & Induced Proximity Summit. Boston (MA): Nurix Therapeutics, Inc; 2024."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147473"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006073"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448332"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800570"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4682.4682"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628669"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190"},{"key":"e_1_3_2_50_1","volume-title":"Updated efficacy and safety data from an ongoing phase 1a\/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy","author":"Munir T","year":"2026","unstructured":"Munir T, Omer Z, Grosicki S, Kwiatek M, Danilov A, Shah N, et\u00a0al., editors. Updated efficacy and safety data from an ongoing phase 1a\/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy. Stockholm, Sweden: European Hematology Association; 2026."},{"key":"e_1_3_2_51_1","volume-title":"Bexobrutideg (NX-5948), a novel Bruton\u2019s tyrosine kinase degrader, shows high clinical activity and tolerable safety in an ongoing phase 1a\/b study in patients with Waldenstr\u00f6m macroglobulinemia","author":"El-Sharkawi D","year":"2025","unstructured":"El-Sharkawi D, Lewis D, Pulles A, et\u00a0al. Bexobrutideg (NX-5948), a novel Bruton\u2019s tyrosine kinase degrader, shows high clinical activity and tolerable safety in an ongoing phase 1a\/b study in patients with Waldenstr\u00f6m macroglobulinemia. Milan, Italy: European Hematology Association; 2025."},{"key":"e_1_3_2_52_1","unstructured":"National Cancer Institute. A Study of NX-5948 in adults with CLL\/SLL previously treated with a bruton\u2019s tyrosine kinase inhibitor and a B-cell lymphoma-2 inhibitor. (DAYBreak CLL-201) [Available from: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2025-09040"},{"key":"e_1_3_2_53_1","volume-title":"Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL","author":"Huynh T","year":"2025","unstructured":"Huynh T, Rodriguez-Rodriguez S, Roleder C, Chen AP, Lam V, Muir A, et\u00a0al., editors. Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL. Krakow, Poland: International Workshop on CLL; 2025."},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179872"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-85"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3583"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3584"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.161"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-26-0251"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007081"},{"key":"e_1_3_2_63_1","volume-title":"Study of NX-5948 in combination with other agents in adults with B-cell malignancies","author":"Nurix Therapeutics I","year":"2026","unstructured":"Nurix Therapeutics I. Study of NX-5948 in combination with other agents in adults with B-cell malignancies. U.S. National Library of Medicine, Johnson & Johnson. 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07520006"},{"key":"e_1_3_2_64_1","unstructured":"Johnson J. U.S. FDA approves IMBRUVICA\u00ae (ibrutinib) plus obinutuzumab as first non-chemotherapy combination regimen for treatment-na\u00efve patients with chronic lymphocytic leukemia; 2019. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/u-s-fda-approves-imbruvica-ibrutinib-plus-obinutuzumab-as-first-non-chemotherapy-combination-regimen-for-treatment-naive-patients-with-chronic-lymphocytic-leukemia"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2743355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2026.2743355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2743355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:37:42Z","timestamp":1791787062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2026.2743355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,11]]},"references-count":63,"alternative-id":["10.1080\/10428194.2026.2743355"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2026.2743355","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}